Compare AstraZeneca plc (AZN) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs The Coca-Cola Co K — how do they compare? AstraZeneca plc trades at $158.08 (market cap $250.84B), while The Coca-Cola Co K trades at $86.45 (market cap $373.76B). The key difference: The Coca-Cola Co K is the larger of the two by market cap, and The Coca-Cola Co K pays the higher dividend (2.44%). Which is the better fit depends on your goals.
| AZN | KO | |
|---|---|---|
Market Cap | $250.84B | $373.76B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $89.08 |
52-Week Low | $147.06 | $65.67 |
Enterprise Value | $278.12B | $400.93B |
Dividend Yield | 1.97% | 2.44% |
Volume | — | 14,630,257 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).
The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.
Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal supported by moving averages and RSI near oversold levels. The company shows strong profitability with a 28.56% net income margin and consistent earnings beats, while analyst consensus is a Buy with a $95.83 price target. Recent news highlights institutional accumulation and stable dividend trends.
The outlook remains positive given earnings momentum and dividend reliability, though risks include regional demand divergence and high valuation multiples. Upside is supported by analyst targets and institutional confidence, but investors should weigh debt levels and competitive pressures in the beverage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
